Archer Aviation Inc vs Cassava Sciences Inc — how do they compare? Archer Aviation Inc trades at $6.18 (market cap $5.23B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Archer Aviation Inc is far larger — about 109.5× Cassava Sciences Inc's market cap, and Archer Aviation Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | FLNA | |
|---|---|---|
Market Cap | $5.23B | $47.75M |
Sector | Industrials | Health |
52-Week High | $13.64 | $4.64 |
52-Week Low | $4.44 | $0.87 |
Enterprise Value | $3.79B | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.29, up 0.48% with strong technical momentum and bullish analyst sentiment. The company reported Q2 2026 revenue of $5 million, beating expectations by 150%, while announcing a transformative Boeing deal acquiring three businesses for a 20% equity stake. Despite negative profitability metrics and substantial cash burn, the strategic expansion into defense and autonomous aviation technology has driven recent stock appreciation.
The outlook remains speculative with significant execution risks, but strategic partnerships and regulatory progress provide potential upside. Investors face dilution concerns from the $750 million equity offering while betting on long-term commercialization of air taxi technology. The stock's valuation appears stretched with P/S ratio of 719.85, requiring successful commercialization to justify current levels.
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →